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Abstract
Deep learning bears promise for drug discovery, including
advanced image analysis, prediction of molecular struc-
ture and function, and automated generation of innova-
tive chemical entities with bespoke properties. Despite the
growing number of successful prospective applications, the
underlying mathematical models often remain elusive to
interpretation by the human mind. There is a demand for
‘explainable’ deep learning methods to address the need
for a new narrative of the machine language of the molec-
ular sciences. This review summarizes the most prominent
algorithmic concepts of explainable artificial intelligence,
and dares a forecast of the future opportunities, potential
applications, and remaining challenges.
1 Introduction
Several concepts of ‘artificial intelligence’ (AI) have been
adopted for computer-assisted drug discovery.1–7 Deep
learning algorithms, i.e., artificial neural networks with
multiple processing layers,8 are currently receiving partic-
ular attention, owing to their capacity to model complex
nonlinear input-output relationships, and perform pattern
recognition and feature extraction from low-level data rep-
resentations.8,9
Certain deep learning models have been shown to match
or even exceed the performance of the existing machine-
learning and quantitative structure-activity relationship
(QSAR) methods for drug discovery.6,10–13 Moreover,
deep learning has boosted the potential and broadened
the applicability of computer-assisted discovery, e.g., for
molecular de novo design,14–16 chemical synthesis plan-
ning,17–19 protein structure prediction,20,21 and macro-
molecular target identification.22–24 The ability to cap-
ture intricate nonlinear relationships between input data
(e.g., chemical structure representations) and the associ-
ated output (e.g., assay readout) often comes at the price
of limited comprehensibility of the resulting model. While
there have been efforts to explain QSARs in terms of al-
gorithmic insights and molecular descriptor analysis,25–34
deep neural network models notoriously elude immediate
accessibility by the human mind.35,36
In an effort to mitigate the lack of interpretability of
deep learning models, attention has been drawn to ex-
plainable artificial intelligence (XAI).37,38 Providing infor-
mative explanations of AI models aims to (i) render the
underlying decision-making process transparent (‘under-
standable’),39 (ii) avoid correct predictions for the wrong
reasons (the so-called ‘clever Hans effect’40), (iii) avert un-
fair biases or unethical discrimination,41 and (iv) bridge
the gap between the machine learning community and
other scientific disciplines. In medicinal chemistry, XAI
already enables the mechanistic interpretation of drug ac-
tion,42,43 and contributes to drug safety enhancement44
and organic synthesis planning.17,45 Intensified efforts to-
wards interpreting deep learning models will help increase
their reliability and foster their acceptance and usage in
drug discovery and medicinal chemistry projects.46–49 The
availability of ‘rule of thumb’ scores correlating biological
effects with physicochemical properties50–54 underscores
the willingness, in certain situations, to sacrifice accuracy
in favour of models that better fit human intuition. Thus,
blurring the lines between the ‘two QSARs’55 (i.e., mech-
anistically interpretable vs. highly accurate models) can
be the key for accelerated drug discovery.56
While the exact definition of XAI is still under de-
bate,41,57 several aspects of XAI are certainly desirable in
drug design applications:37 (i) transparency, i.e., knowing
how the system reached a particular answer, (ii) justifi-
cation, i.e., elucidating why the answer provided by the
model is acceptable, (iii) informativeness, i.e., providing
new information to human decision-makers, and (iv) un-
certainty estimation, i.e., the quantification of how reliable
a prediction is. Moreover, AI model explanations can be
global (i.e., summarizing the relevance of input features in
the model) or local (i.e. on individual predictions).58 Fur-
thermore, XAI can be model-dependent or agnostic, which
in turn affects the potential applicability of each method.
The field of XAI is still in its infancy but moving for-
ward at a fast pace, and we expect an increase of its rel-
evance in the years to come. In this review, we aim to
provide a comprehensive overview of recent XAI research,
including its benefits, limitations and future opportunities
for drug discovery. In what follows, after providing an in-
troduction to the most relevant XAI methods structured
into conceptual categories, the existing and some of the
potential applications to drug discovery are highlighted.
Finally, we discuss the limitations of contemporary XAI
and point to the potential methodological improvements
needed to foster practical applicability of these techniques
to pharmaceutical research.
2 State of the art
This section aims to provide a concise overview of mod-
ern XAI approaches, and exemplify their use in computer
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Table 1: Computational approaches toward explainable AI, categorized according to the respective methodological
concept. For each family of approaches, a brief description of its aim is provided, its specific methods, and reported
applications in drug discovery. ‘Not reported ’ refers to families of methods that, to the best of our knowledge, have
not been yet applied in drug discovery. Potential applications of these are discussed in the main text.
Family Aim Methods Reported applications in drug discovery
Feature attribution Determine local feature
importance towards a prediction.
- Gradient-based Ligand pharmacophore identification,59–61
structural alerts for adverse effect,62
protein-ligand interaction profiling.63
- Surrogate models
- Perturbation-based
Instance-based Compute a subset of features that
need to be present or absent to
guarantee or change a prediction.
- Anchors Not reported
- Counterfactual instances
- Contrastive explanations
Graph-convolution-based Interpret models within the
message-passing framework.
- Sub-graph approaches Retrosynthesis elucidation,64 toxicophore and
pharmacophore identification,49 ADMET,65,66
and reactivity prediction.19
- Attention-based
Self-explaining Develop models that are
explainable by design.
- Prototype-based Not reported
- Self-explaining neural networks
- Concept learning
- Natural language explanations
Uncertainty estimation Quantify the reliability of a
prediction.
- Ensemble-based Reaction prediction,67 active learning,68
molecular activity prediction.69
- Probabilistic
- Other approaches
vision, natural-language processing, and discrete mathe-
matics. We then highlight selected case studies in drug
discovery and propose potential future areas of XAI re-
search. A summary of the methodologies and their goals,
along with reported applications is provided in Table 1.
In what follows, without loss of generality, f will denote a
model (in most cases a neural network); x ∈ X will be used
to denote the set of features describing a given instance,
which are used by f to make a prediction y ∈ Y.
2.1 Feature attribution methods
Given a regression or classification model f : x ∈ RK → R,
a feature attribution method is a function E : x ∈ RK →
RK that takes the model input and produces an output
whose values denote the relevance of every input feature
for the final prediction computed with f . Feature attri-
bution methods can be grouped into the following three
categories (Figure 1):
• Gradient-based feature attribution. These approaches
measure how much a change around a local neigh-
borhood of the input x corresponds to a change in
the output f(x). A common approach among deep-
learning practitioners relies on the use of the deriva-
tive of the output of the neural network with re-
spect to the input (i.e.,
δf
δx
) to determine feature
importance.70–72 Its popularity arises partially from
the fact that this computation can be performed via
backpropagation,73 the main way of computing par-
tial first-order derivatives in neural network models.
While the use of gradient-based feature attribution
may seem straightforward, several methods relying on
this principle have been shown to lead to only par-
tial reconstruction of the original features,74 which is
prone to misinterpretation.
• Surrogate-model feature attribution. Given a model f ,
these methods aim to develop a surrogate explanatory
model g, which is constructed in such a way that: (i) g
is interpretable, and (ii) g approximates the original
function f . A prominent example of this concept is
the family of additive feature attribution methods,
where the approximation is achieved through a linear
combination of binary variables zi:
g
(
z
′
i
)
= φ0 +
M∑
i=1
φizi, (1)
where zi ∈ {0, 1}M , M is the number of original in-
put features, φi ∈ R are coefficients representing the
importance assigned to each i -th binary variable and
φ0 is an intercept. Several notable feature attribution
methods belong to this family,75,76 such as Local In-
terpretable Model-Agnostic Explanations (LIME),77
Deep Learning Important FeaTures (DeepLIFT),78
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Figure 1: Feature attribution methods. Given a neural
network model f , which computes the prediction y = f(x)
for input sample x, a feature attribution method E out-
puts the relevance of every input feature of x for the pre-
diction. There are three basic approaches to determine
feature relevance: (a) gradient-based methods, comput-
ing the gradient of the network f w.r.t. the input x, (b)
surrogate methods, which approximate f with a human-
interpretable model g, and (c) perturbation-based meth-
ods, which modify the original input to measure the re-
spective changes in the output.
Shapley Additive Explanations (SHAP)76 and Layer-
Wise Relevance Propagation.79 Both gradient-based
methods and the additive subfamily of surrogate at-
tribution methods provide local explanations (i.e.,
each prediction needs to be examined individually),
but they do not offer a general understanding of
the underlying model f . Global surrogate explanation
models aim to fill this gap by generically describing f
via a decision tree or decision set80 model. If such an
approximation is precise enough, these aim to to mir-
ror the computation logic of the original model. While
early attempts limited f to the family of tree-based
ensemble methods (e.g., random forests81), more re-
cent approaches are readily applicable to arbitrary
deep learning models.82
• Perturbation-based methods modify or remove parts of
the input aiming to measure its corresponding change
in the model output; this information is then used
to assess the feature importance. Alongside the well-
established step-wise approaches,83–85 methods such
as feature masking,86 perturbation analysis,87 re-
sponse randomization,88 and conditional multivariate
models89 belong to this category. While perturbation-
based methods have the advantage of directly esti-
mating feature importance, they are computationally
slow when the number of input features increases,89
and the final result tends to be strongly influenced
by the number of features that are perturbed alto-
gether.90
Feature attribution methods have been used for ligand-
and structure-based drug-discovery. For instance, Mc-
Closkey et al.59 employed gradient-based attribution70 to
detect ligand pharmacophores relevant for binding. The
study showed that, despite good performance of the mod-
els on held-out data, these still can learn spurious corre-
lations.59 Pope et al.62 adapted gradient-based feature at-
tribution91,92 for the identification of relevant functional
groups in adverse effect prediction.93 Recently, SHAP76
was used to interpret relevant features for compound po-
tency and multiâĂŚtarget activity prediction.60,61 Hochuli
et al.63 compared several feature attribution methodolo-
gies, showing how the visualization of attributions assists
in parsing and interpreting of protein-ligand scoring with
3D convolutional neural networks.94,95
It should be noted that the interpretability of feature
attribution methods is limited by the original set of fea-
tures (model input). In drug discovery the interpretability
of machine learning methods is often hampered by the use
of complex input molecular descriptors. When making use
of feature attribution approaches, it is advisable to choose
molecular descriptors or representations for model con-
struction that one considers to bear ‘interpretable mean-
ing’ (Box 1).
2.2 Instance-based approaches
Instance-based approaches compute a subset of relevant
features (instances) that must be present to retain (or ab-
sent to change) the prediction of a given model (Figure 2).
An instance can be real (i.e., drawn from the set of data)
or generated for the purposes of the method. Instance-
based approaches have been argued to provide ‘natural’
model interpretations for humans, because they resemble
counterfactual reasoning (i.e. producing alternative sets of
action to achieve a similar or different result).96
• Anchor algorithms97 offer model-agnostic inter-
pretable explanations of classifier models. They com-
pute a subset of if -then rules based on one or more
features that represent conditions to sufficiently guar-
antee a certain class prediction. In contrast to many
other local explanation methods,77 anchors therefore
explicitly model the ‘coverage’ of an explanation. For-
mally, an anchor A is defined as a set of rules such
that, given a set of features x from a sample, they re-
turn A(x) = 1 if said rules are met, while guarantee-
ing the desired predicted class from f with a certain
probability τ :
ED(z|A)
[
1f(x)=f(z)
] ≥ τ, (2)
where D(z|A) is defined as the conditional distribu-
tion on samples where anchor A applies. This method-
ology has successfully been applied in several tasks
such as image recognition, text classification, and vi-
sual question answering.97
• Counterfactual instance search. Given a classifier
model f and an original data point x, counterfactual
instance search98 aims to find examples x′ that (i) are
as close to x as possible, and (ii) for which the clas-
sifier produces a different class label from the label
assigned to x. In other words, a counterfactual de-
scribes small feature changes in sample x such that it
is classified differently by f . The search for the set of
instances x′ may be cast into an optimization prob-
lem:
min
x′
max
λ
(ft − pt)2 + λL1 (x′, x) , (3)
where ft is the prediction of the model for the t-th
class, pt a user-defined target probability for the same
3
x c
Input Predicted class
f
x cf
x' c'f
Model
Anchor
Counterfactual
Figure 2: Instance-based model interpretation. Given a
model f , input instance x and the respective predicted
class c, so-called anchor algorithms identify a minimal sub-
set of features of x that are sufficient to preserve the pre-
dicted class assignment c. Counterfactual search generates
a new instance x′ that lies close in feature space to x but
is classified differently by the model, as belonging to class
c′.
class, L1 the Manhattan distance between the pro-
posed x′ and the original sample x, and λ an optimiz-
able parameter that controls the contribution of each
term in the loss. The first term in this loss encourages
the search towards points that change the prediction
of the model, while the second ensures that both x
and x′ lie close to each other in their input manifold.
While in the original paper this approach was shown
to successfully obtain counterfactuals in several data
sets, the results revealed a tendency to look artifi-
cial. A recent methodology99 mitigates this problem
by adding extra terms to the loss function with an au-
toencoder architecture,100 to better capture the origi-
nal data distribution. Importantly, counterfactual in-
stances can be evaluated using trust scores (cf. the
section on uncertainty estimation). One can interpret
a high trust score as the counterfactual being far from
the initially predicted class of x compared to the class
assigned to the counterfactual x′.
• Contrastive explanation methods101 provide instance-
based interpretability of classifiers by generating ‘per-
tinent positive’ (PP) and ‘pertinent negative’ (PN)
sets. This methodology is, therefore, related to both
anchors and counterfactual search approaches. PPs
are defined as the smallest set of features that should
be present in an instance in order for the model to
predict a ‘positive’ result (similar to anchors). Con-
versely, PNs identify the smallest set of features that
should be absent in order for the model to be able to
sufficiently differentiate from the other classes (simi-
lar to a counterfactual instance). This method gener-
ates explanations of the form "An input x is classi-
fied as class y because a subset of features x1, . . . , xk is
present, and because a subset of features xm, . . . , xp is
absent."96,102. Contrastive explanation methods find
such sets by solving two separate optimization prob-
lems, namely by (i) perturbing the original instance
until it is predicted differently than its original class,
and (ii) searching for critical features in the original
input (i.e., those features that guarantee a predic-
tion with a high degree of certainty). The proposed
approach uses an elastic net regularizer,103 and op-
tionally a conditional autoencoder model104 so that
the found explanations are more likely to lie closer to
the original data manifold.
To the best of our knowledge, instance-based approaches
have yet to be applied to drug-discovery. In our opinion,
they bear promise in several areas of de novo molecular
design, such as (i) activity cliff prediction,105,106 as they
can help identify small structural variations in molecules
that cause large bioactivity changes, (ii) fragment-based
virtual screening,107 by highlighting a minimal subset of
atoms responsible for a given observed activity), and (iii)
hit-to-lead optimization, by helping identify the minimal
set of structural changes required to improve one or more
biological or physicochemical properties.
2.3 Graph-convolution-based methods
Molecular graphs are a natural mathematical representa-
tion of molecular topology, with nodes and edges repre-
senting atoms and chemical bonds, respectively108 (Fig-
ure 3a). Furthermore, their usage has been commonplace
in chemoinformatics and mathematical chemistry since
the late 1970s.109–112 Thus, it does not come as a sur-
prise in these fields to witness the increasing application
of novel graph-convolution neural networks,113 which for-
mally fall under the umbrella of neural-message passing
algorithms.114–116 Generally speaking, convolution refers
to a mathematical operation on two functions that pro-
duces a third function expressing how the shape of one
is modified by the other. This concept is widely used in
convolutional neural networks for image analysis. Graph
convolutions naturally extend the convolution operation
typically used in computer vision117 or in natural language
processing118 applications to arbitrarily-sized graphs. In
the context of drug discovery, graph convolutions have
been applied to molecular property prediction119,120 and
in generative models for de novo drug design.121
Exploring the interpretability of models trained with
graph-convolution architectures is currently a particularly
active research topic. For the purpose of this review, XAI
methods based on graph-convolution are grouped into the
following two categories:
• Sub-graph identification approaches aim to identify
one or more parts of a graph that are responsible
for a given prediction (Figure 3b). GNNExplainer122
is a model-agnostic example of such category, and
provides explanations for any graph-based machine
learning task. Given an individual input graph, GN-
NExplainer identifies a connected sub-graph struc-
ture, as well a set of node-level features that are rele-
vant for a particular prediction. The method can also
provide such explanations for a group of data points
belonging to the same class. GNNExplainer is formu-
lated as an optimization problem, where a mutual in-
formation objective between the prediction of a graph
neural network and the distribution of feasible sub-
graphs is maximized. Mathematically, given a node
v, the goal is to identify a sub-graph GS ⊆ G with
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associated features XS = {xj |vj ∈ GS} that are rel-
evant in explaining a target prediction yˆ ∈ Y via a
mutual information measure MI:
max
GS
MI (Y, (GS , XS)) = H(Y )−
H(Y |G = GS , X = XS). (4)
In practice, however, this objective is not mathe-
matically tractable, and several continuity and con-
vexity assumptions have to be made. GNNExplainer
was tested on a set of molecules labeled for their
mutagenic effect on Salmonella typhimurium,123 and
identified several known mutagenic functional groups
(i.e., certain aromatic and heteroaromatic rings and
amino/nitro groups123) as relevant.
• Attention-based approaches. The interpretation of
graph-convolutional neural networks can benefit from
attention mechanisms,124 which borrow from the nat-
ural language processing field, where their usage has
become standard.125 The idea is to stack several
message-passing layers to obtain hidden node-level
representations, by first computing attention coeffi-
cients associated with each of the edges connected
to the neighbors of a particular node in the graph
(Figure 3c). Mathematically, for a given node, an
attention-based graph convolution operation obtains
its updated hidden representation via a normalized
sum of the node-level hidden features of the topolog-
ical neighbours:
h
(l+1)
i = σ
 ∑
j∈N (i)
αlijW
(l)h
(l)
j
 , (5)
where N (i) is the set of topological neighbours of
node i with a one-edge distance, αlij are learned at-
tention coefficients over those neighbours, σ is a non-
linear activation function, and W (l) is a learnable
feature matrix for layer l. The main difference be-
tween this approach and a standard graph convolu-
tion update is that, in the latter, attention coeffi-
cients are replaced by a fixed normalization constant
cij =
√|N (i)|√|N (j)|.
A recent study49 describes how the interpretation of fil-
ters in message-passing networks can lead to the identifica-
tion of relevant pharmacophore- and toxicophore-like sub-
structures, showing consistent findings with literature re-
ports. Gradient-based feature attribution techniques, such
as Integrated Gradients,70 were used in conjunction with
graph-convolutional networks to analyze retrosynthetic re-
action predictions and highlight the atoms involved in
each reaction step.64 Attention-based graph convolutional
neural networks have also been used for the prediction
of solubility, polarity, synthetic accessibility, and photo-
voltaic efficiency, among other properties,65,66 leading to
the identification of relevant molecular substructures for
the target properties. Finally, attention-based graph ar-
chitectures have also been used in chemical reactivity pre-
diction,19 pointing to structural motifs that are consistent
Figure 3: Graph-based model interpretation. (a) Kekulé
structure of adrenaline and its respective molecular graph;
atoms and bonds constitute nodes and edges, respec-
tively. (b) Given an input graph, approaches like GNNEx-
plainer122 aim to identify a connected, compact subgraph,
as well as node-level features that are relevant for a partic-
ular prediction y of a graph-neural network model f . (c)
Attention mechanisms can be used in conjunction with
message-passing algorithms in order to learn coefficients
α
(l)
ij for the l-th layer, which assign ’importance’ to the
set of neighbours N (i) (e.g., adjacent atoms) of a node i.
These coefficients are an explicit component in the compu-
tation of new hidden-node representations h(l+1)i (Eq. (5))
in attention-based graph-convolutional architectures. Such
learned attention coefficients can be then used to highlight
the predictive relevance of certain edges and nodes.
with a chemist’s intuition in the identification of suitable
reaction partners and activating reagents.
Due to their intuitive connection with the two-
dimensional representation of molecules, graph-
convolution-based XAI bears the potential of being
applicable in many common modeling tasks in drug
discovery. Some of the applications that might benefit
most from the usage of these approaches are those aiming
to identify relevant structural molecular motifs, e.g., for
structural alert identification,126 site of reactivity127 or
metabolism128 prediction, and the selective optimization
of side activities.129
2.4 Self-explaining approaches
The XAI methods introduced so far produce a posteriori
explanations of deep learning models. Although such post-
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hoc interpretations have been shown to be useful, some
argue that, ideally, XAI methods, should automatically
offer human-interpretable explanation alongside their pre-
dictions.130 Such approaches (herein referred to as ‘self-
explaining ’) would promote verification and error analysis,
and be directly linkable with domain knowledge.131 While
the term self-explaining has been coined to refer to a spe-
cific neural network architecture – self-explaining neural
networks,131 described below – in this review, the term is
used in a broader sense, so as to identify methods that
feature interpretability as a central part of their design.
Self-explaining XAI approaches can be grouped into the
following categories:
• Prototype-based reasoning refers to the task of fore-
casting future events (i.e., novel samples) based on
particularly informative known data points. Usually,
this is done by identifying prototypes, i.e., represen-
tative samples, which are adapted (or used directly)
to make a prediction. These methods are motivated
by the fact that predictions based on individual, pre-
viously seen examples mimic human decision mak-
ing.132 The Bayesian case model,133 is a pre-deep-
learning approach that constitutes a general frame-
work for such prototype-based reasoning. A Bayesian
case model learns to identify observations that best
represent clusters in a dataset (i.e., prototypes), along
with a set of defining features for that cluster. Joint
inference is performed on cluster labels, prototypes,
and extracted relevant features, thereby providing in-
terpretability without sacrificing classification accu-
racy.133 Recently, Li et al.134 developed a neural net-
work architecture composed of an autoencoder and
a therein named ‘prototype layer’, whose units store
a learnable weight vector representing an encoded
training input. Distances between the encoded latent
space of new inputs and the learned prototypes are
then used as part of the prediction process. This ap-
proach was later expanded by Chen et al.135 to con-
volutional neural networks for computer vision tasks.
• Self-explaining neural networks131 aim to associate
input or latent features with semantic concepts. They
jointly learn a class prediction and generate explana-
tions using a feature-to-concept mapping. Such a net-
work model consists of (i) a sub-network that maps
raw inputs into a predefined set of explainable con-
cepts, (ii) a parameterizer that obtains coefficients for
each individual explainable concept, and (iii) an ag-
gregation function that combines the output of the
previous two components to produce the final class
prediction.
• Human-interpretable concept learning refers to the
task of learning a class of concepts, i.e. high-level com-
binations of knowledge elements136) from data, aim-
ing to achieve human-like generalization ability. The
Bayesian Program Learning approach137 was pro-
posed with the goal of learning visual concepts in com-
puter vision tasks. Such concepts were represented as
probabilistic programs expressed as structured pro-
cedures in an abstract description language.138 The
model then composes more complex programs us-
ing the elements of previously learned ones using
a Bayesian criterion. This approach was shown to
reach human-like performance in one-shot learning
tasks.139,140
• Testing with concept activation vectors141 computes
the directional derivatives of the activations of a layer
w.r.t. its input, towards the direction of a concept.
Such derivatives quantify the degree to which the lat-
ter is relevant for a particular classification (e.g., how
important the concept ‘stripes’ is for the prediction of
the class ‘zebra’). It does so by considering the math-
ematical association between the internal state of a
machine learning model – seen as a vector space Em
spanned by basis vectors em that correspond to neural
activations – and human-interpretable activations re-
siding in a different vector space Eh spanned by basis
vectors eh. A linear function is computed that trans-
lates between these vector spaces (g : Em → Eh). The
association is achieved by defining a vector in the di-
rection of the values of a concept’s set of examples,
and then training a linear classifier between those and
random counterexamples, to finally take the vector
orthogonal to the decision boundary.
• Natural language explanation generation. Deep
networks can be designed to generate human-
understandable explanations in a supervised man-
ner.142 In addition to minimizing the loss of the main
modeling task, several approaches synthesize a sen-
tence using natural language that explains the deci-
sion performed by the model, by simultaneously train-
ing generators on large data sets of human-written
explanations. This approach has been applied to gen-
erate explanations that are both image- and class-
relevant.143 Another prominent application is visual
question answering.144 To obtain meaningful expla-
nations, however, this approach requires a significant
amount of human-curated explanations for training,
and might, thus, find limited applicability in drug dis-
covery tasks.
To the best of our knowledge, self-explaining deep learn-
ing has not been applied to chemistry or drug design yet.
Including interpretability by design could help bridge the
gap between machine representation and the human un-
derstanding of many types of problems in drug discov-
ery. For instance, prototype-reasoning bears promise in the
modeling of heterogeneous sets of chemicals with different
modes of action, allowing to preserve both mechanistic
interpretability and predictive accuracy. Explanation gen-
eration (either concept- or text-based) is another poten-
tial solution to include human-like reasoning and domain
knowledge in the model building task. In particular, expla-
nation generation approaches might be applicable to cer-
tain decision-making processes, such as the replacement of
animal testing and in-vitro to in-vivo extrapolation, where
human-understandable generated explanations constitute
a crucial element.
2.5 Uncertainty estimation
Uncertainty estimation, i.e. the quantification of epistemic
error in a prediction, constitutes another approach to
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model interpretation. While some machine learning algo-
rithms, such as Gaussian processes,145 provide built-in un-
certainty estimation, deep neural networks are known for
being poor at quantifying uncertainty.146 This is one of the
reasons why several efforts have been devoted to specifi-
cally quantify uncertainty in neural network-based pre-
dictions. Uncertainty estimation methods can be grouped
into the following categories:
• Ensemble approaches. Model ensembles improve the
overall prediction quality and have become a standard
for uncertainty estimates.147 Deep ensemble averag-
ing148 is based on m identical neural network models
that are trained on the same data and with a different
initialization. The final prediction is obtained by ag-
gregating the predictions of all models (e.g., by aver-
aging), while an uncertainty estimate can be obtained
from the respective variance (Figure 4a). Similarly,
the sets of data on which these models are trained can
be generated via bootstrap re-sampling.149 A disad-
vantage of this approach is its computational demand,
as the underlying methods build on m independently
trained models. Snapshot ensembling150 aims to over-
come this limitation by periodically storing model
states (i.e. model parameters) along the the train-
ing optimization path. These model ‘snapshots’ can
be then used for constructing the ensemble.
• Probabilistic approaches aim to estimate the posterior
probability of a certain model output or to perform
post-hoc calibration. Many of these methods treat
neural networks as Bayesian models, by considering a
prior distribution over its learnable weights, and then
performing inference over their posterior distribu-
tion with various methods (Figure 4b), e.g., Markov
Chain Monte Carlo151 or variational inference.152,153
Gal et al.,154 suggested the usage of dropout regular-
ization to perform approximate Bayesian inference,
which was later extended155 to compute epistemic
(i.e., caused by model mis-specification) and aleatory
uncertainty (inherent to the noise in the data). Sim-
ilar approximations can also be made via batch nor-
malization.156 Mean variance estimation157 considers
a neural network designed to output both a mean and
variance value, to then train the model using a neg-
ative Gaussian log-likelihood loss function. Another
subcategory of approaches consider asymptotic ap-
proximations of a prediction by making Gaussian dis-
tributional assumptions of its error, such as the delta
technique.158,159
• Other approaches. The LUBE (lower upper bound es-
timation)160 approach trains a neural network with
two outputs, corresponding to the upper and lower
bounds of the prediction. Instead of quantifying the
error of single predictions, LUBE uses simulated
annealing and optimizes the model coefficients to
achieve (a) maximum coverage (probability that the
real value of the i-th sample will fall between the up-
per and the lower bound) of training measurements
and (b) minimum prediction interval width. Ak et
al. suggested to quantify the uncertainty in neural
network models by directly modelling interval-valued
data.161 Trust scores162 measure the agreement be-
tween a neural network and a k-nearest neighbour
Figure 4: Uncertainty estimation. (a) Ensemble-based
methods aggregate the output of m identical, but
differently-initialized, models fi. The final prediction is ob-
tained by aggregating the predictions of all models (e.g., as
the average, y¯), while an uncertainty estimate can be ob-
tained from the respective predictive variance, e.g., in the
form of a standard deviation, sd(y). (b) Bayesian proba-
bilistic approaches consider a prior p(θ) over the learnable
weights of a neural network model fθ, and make use of
approximate sampling approaches to learn a posterior dis-
tribution over both the weights p(θ|x) and the prediction
pθ(y|x). These distributions can be then sampled from to
obtain uncertainty estimates over both the weights and
the predictions.
classifier that is trained on a filtered subset of the
original data. The trust score considers both the dis-
tance between the instance of interest to the nearest
class that is different from the original predicted one
and its distance towards the predicted class. Union-
based methods163 first train a neural network model
and then feed its embeddings to a second model that
handles uncertainty, such as a Gaussian process or a
random forest. Distance-based approaches164 aim to
estimate the prediction uncertainty of a new sample
x′ by measuring the distance to the closest sample in
the training set, either using input features165 or an
embedding produced by the model.166
Many uncertainty estimation approaches have been suc-
cessfully implemented in drug discovery applications,167
mostly in traditional QSAR modeling, either by the use
of models that naturally handle uncertainty168 or post-
hoc methods.169–171 Attention has recently been drawn to-
ward the development of uncertainty-aware deep-learning
applications in the field. ’Snapshot ensembling’ was ap-
plied to model 24 bioactivity datasets,172 showing that it
performs on par with random forest and neural network
ensembles, and also leads to narrower confidence inter-
vals. Schwaller et al.67 proposed a transformer model173
for the task of forward chemical reaction prediction. This
approach implements uncertainty estimation by comput-
ing the product of the probabilities of all predicted tokens
in a SMILES sequence representing a molecule. Zhang
et al.68 have recently proposed a Bayesian treatment of
a semi-supervised graph-neural network for uncertainty-
calibrated predictions of molecular properties, such as the
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melting point and aqueous solubility. Their results suggest
that this approach can efficiently drive an active learning
cycle, particularly in the low-data regime – by choosing
those molecules with the largest estimated epistemic un-
certainty.
Importantly, a recent comparison of several uncertainty
estimation methods for physicochemical property predic-
tion showed that none of the methods systematically out-
performed all others.174
3 Available software
Given the attention deep learning applications are cur-
rently receiving, several software tools have been devel-
oped to facilitate model interpretation. A prominent ex-
ample is Captum,175 an extension of the PyTorch176 deep-
learning and automatic differentiation package that pro-
vides support for most of the feature attribution tech-
niques described in this work. Another popular package
is Alibi,177 which provides instance-specific explanations
for certain models trained with the scikit-learn178 or Ten-
sorFlow179 packages. Some of the explanation methods im-
plemented include anchors, contrastive explanations, and
counterfactual instances.
4 Conclusions and outlook
Automated analysis of medical and chemical knowledge to
extract and present features in a human-readable format
dates back to the 1990s,180,181 but it’s receiving increasing
attention in the last years due to the renaissance of neural
networks in chemistry and healthcare. Given the current
pace of AI in drug discovery and related fields, there will be
an increased demand for methods that help us understand
and interpret deep learning models.
For drug discovery and design in particular, XAI
will foster collaborations between medicinal chemists,
chemoinformaticians and data scientists. If successful, XAI
bears the potential to provide fundamental support in
the analysis and interpretation of increasingly more com-
plex chemical data, as well as in the formulation of new
pharmacological hypotheses, while avoiding human bi-
ases.182,183 At the same time, novel drug discovery chal-
lenges might boost the development of application-tailored
XAI approaches, to promptly respond to specific scientific
questions related to human biology and pathophysiology.
It will be important to explore the opportunities and
limitations of the established chemical language for repre-
senting the decision space of these models. Additionally,
we have to concede our incomplete understanding of the
human pathology at the molecular level, with all its in-
dividual idiosyncrasies. In this context, full comprehen-
sibility may be hard to achieve, given, for instance, the
often nonlinear relationships between chemical structure
and pharmacological activity, the presence of error, and
limited predictability.184
XAI also poses technical challenges, given the multiplic-
ity of possible explanations and methods applicable to a
given task.185 Most approaches do not come as readily
usable out-of-the-box solutions, but need to be tailored to
each individual application. Additionally, profound knowl-
edge of the problem domain is crucial to identify which
model decisions demand further explanations, which type
of answers are meaningful to the user and which are in-
stead trivial or expected.186 For human decision making,
the explanations generated with XAI have to be non-
trivial, non-artificial, and sufficiently informative for the
respective scientific community. At least for the time be-
ing, finding such solutions will require the collaborative
efforts of deep-learning experts, chemoinformaticians and
data scientists, chemists, biologists and other domain ex-
perts, to ensure that XAI methods serve their intended
purpose and deliver reliable answers.
A crucial challenge for future AI-assisted drug discov-
ery is the data representation used for machine and deep
learning. In contrast to many other areas in which deep
learning has been shown to excel, such as natural lan-
guage processing and image recognition, there is no nat-
urally applicable, complete, ‘raw’ molecular representa-
tion. After all, molecules – as scientists conceive them –
are models themselves. Such ‘induction-based’ approach,
which builds higher-order (e.g., deep learning) models
from lower-order ones (e.g., molecular representations or
descriptors based on observational statements) is there-
fore philosophically debatable.187 The question as to how
to represent molecules for deep learning thus constitutes
still one of the fundamental challenges of XAI in drug dis-
covery and design.
One step forward towards explainable AI is to build
on interpretable ‘low-level’ molecular representations
that have direct meaning for chemists (e.g. SMILES
strings,188,189 amino acid sequences,190,191 and spatial
3D-voxelized representations94,192). Many recent studies
also rely on well-established molecular descriptors, such
as hashed binary fingerprints193,194 and topochemical
and geometrical descriptors,195,196 which capture struc-
tural features defined a priori. Often, molecular descrip-
tors, while being relevant for subsequent modeling, cap-
ture complex chemical information in a non readily-
interpretable way. Consequently, when striving for XAI,
there is an understandable tendency to employ molecular
representations that are more easily interpretable in terms
of the known language of chemistry.197 It therefore goes
without saying that the development of novel interpretable
molecular representations for deep learning will constitute
a critical area of research for the years to come, including
the development of self-explaining approaches to overcome
the hurdles of non-interpretable but information-rich de-
scriptors, by providing human-like explanations alongside
sufficiently accurate predictions.
Most of the deep learning models in drug discovery do
not consider applicability domain issues,198 i.e., the region
of chemical space where statistical learning assumptions
are met.199 Inclusion of applicability domain restrictions –
in an interpretable way, whenever possible – should be con-
sidered as an integral element of explainable AI. Knowing
when to apply which particular model will, in fact, help
address the problem of high confidence of deep learning
models on wrong predictions,146,200,201 avoiding unneces-
sary extrapolations at the same time. Assessing a model’s
applicability domain and rigorous determination of model
accuracy might arguably be more important for decision
making than the particular modeling approach chosen.69
At present, XAI in drug discovery is lacking open-
community platforms, where software code, model inter-
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pretations, and the respective training data can be shared
and improved by synergistic efforts of researchers with dif-
ferent scientific backgrounds. Initiatives like MELLODDY
(Machine Learning Ledger Orchestration for Drug Dis-
covery) for decentralized, federated model development
and secure data handling across pharmaceutical compa-
nies constitute a first step in the right direction.202 Such
kinds of collaboration will hopefully foster the validation
and acceptance of XAI approaches and the associated ex-
planations they provide.
Especially in time- and cost-sensitive scenarios like drug
discovery, the users of deep learning methods have the re-
sponsibility to cautiously inspect and interpret the pre-
dictions made by such a computational model. Keeping
in mind the possibilities and limitations of drug discovery
with XAI, it is reasonable to assume that the continued
development of alternative models that are more easily
comprehensible and computationally affordable will not
lose its importance.
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Box 1: Explainable AI (XAI) applied to cytochrome P450 metabolism.
This worked example showcases XAI that provides a graphical explanation in terms of molecular motifs that are
considered relevant by a neural network model predicting drug interaction with cytochrome P450 (3A4 isoform,
CYP3A4). The integrated gradients feature attribution method70 was combined with a graph-convolutional
neural network for predicting drug-CYP3A4 interaction. This network model was trained with a publicly
available set of CYP3A4 substrates and inhibitors.203 The figure shows the results obtained for two drugs that
are metabolized predominantly by CYP3A4, namely the phosphodiesterase A inhibitor (antiplatelet agent)
cilostazol,204 and nifedipine,205 an L-type calcium channel blocker.
The structural features for CYP3A4-compound interaction suggested by the XAI method are highlighted in
color (left panel ‘in silico’: blue, positive contribution to interaction with CYP3A4; orange, negative contribution
to interaction; spot size indicates the feature relevance of the respective atom). The main sites of metabolism
(dashed circles) and the known metabolites204,206–208 are shown in the right panel (‘experimental’). Apparently,
the XAI captured the chemical substructures involved in CYP3A4-mediated biotransformation and most of the
known sites of metabolism. Additional generic features related to metabolism were identified, i.e., (i) the
tetrazole moiety and the secondary amino group in cilostazol, which are known to increase metabolic stability
(left panel : orange, negative contribution to the CYP3A4 -cilostazol interaction), and (ii) metabolically labile
groups, such as methyl and ester groups (left panel : blue, positive contribution to the CYP3A4-nifedipine
interaction).
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